Low- dose Pioglitazone improves NAFLD in type 2 diabetes: Study
Complete 1-year treatment with low- dosage pioglitazone shows significant improvement in non-alcoholic fatty liver disease independent of glycaemic control level, suggests a study published in the Diabetes Research and Clinical Practice.
Non-Alcoholic Fatty Liver Disease (NAFLD) and type 2 diabetes have similar pathophysiological mechanisms and potential treatment methods.
A study was performed by Pepa G et. al to assess the effects of 1-year treatment with pioglitazone or sulphonylureas on indirect indices of NAFLD in patients with type-2 diabetes and the role of insulin resistance as well as glucotoxicity in determining these effects.
The researchers selected a total of 195 type-2 diabetes patients belonging to the age group of 50-75 years, with inadequately controlled blood sugar levels and receiving metformin 2 g/day. All the participants were randomly allocated to either add-on pioglitazone (n=98) or sulphonylureas (n=97) within the TOSCA.IT trial.
Plasma insulin, glucose, and liver enzymes were measured at baseline and after 1-year. Indirect indices of NAFLD (Liver Fat Equation [LFE], Hepatic Steatosis Index [HSI], and Index of NASH [ION]), and insulin resistance (HOMA-IR, Visceral Adiposity Index [VAI] and adipose tissue Insulin Resistance [ADIPO-IR]) were calculated.
The findings of the study are as follows:
· NAFLD indices improved after pioglitazone, but not after sulphonylureas; Indices of insulin resistance decreased after pioglitazone, but not after sulphonylureas.
· Changes in NAFLD indices were similar with different doses of pioglitazone (15, 30, or 45 mg/day), and were independent of blood glucose control level.
The researchers concluded that one-year treatment with pioglitazone even at low dosage drastically improved liver steatosis, inflammation, systemic and adipose tissue insulin resistance in patients with type-2 diabetes. Also, the beneficial effects of pioglitazone on NAFLD was independent of blood glucose control level.
Reference:
A study titled, "Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomized trial" by Pepa G et. al published in the Diabetes Research and Clinical Practice
DOI: https://doi.org/10.1016/j.diabres.2021.108984
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.